Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation of the additional Phase 3 trial required to support a submission for U.S. registration of OTIVIDEX in Ménière’s disease.
Linical and Accelovance recently merged to create a leading midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance America, Europe, Romania and China. Additionally, Vita M. Lanoce, M.S., has been appointed as chief executive officer of Linical Accelovance Group.
SHYFT Analytics, a Medidata Solutions company, announced recently that Novartis has selected its Intelligent Platform for Life Sciences to support the commercialization of key therapies in Europe.
The National Institutes of Health’s Health Care Systems (HCS) Research Collaboratory, which involves health care systems in conducting large-scale clinical studies, has announced five new research awards — totaling $4.15M for a one-year planning phase, with an estimated $30.85M expected for four subsequent years of study implementation.
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient was dosed in a global Phase 3 clinical trial of pamiparib, an investigational PARP inhibitor, as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer who responded to platinum-based first-line chemotherapy.
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the treatment of the first patients in Study 206, an open-label Phase 2 basket study evaluating ALLN-177 in adults and adolescents with primary hyperoxaluria, or enteric hyperoxaluria with advanced chronic kidney disease and elevated plasma oxalate.
Sangamo Therapeutics, Inc. and TxCell S.A. announced recently that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of EUR 2.58 per share in cash, or approximately EUR 72 million, on a debt-free and cash-free basis.
ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies—ClaimIt.
Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.
DoseSmart Inc. announced recently that their proprietary medication adherence technology is currently being used in a new clinical trial (clinicaltrials.gov ID NCT03460587) which focuses on helping stroke survivors comply to their medication regime.
|
|
|
|
|
|
|
|
|